No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire

[MEDPAGE TODAY]( Oncology Update Friday, August 09, 2024 [No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire]( [Heavy Cannabis Use Tied to Increased Head and Neck Cancer Risk]( [IL-2 Receptor-Targeted Therapy Approved for Relapsed/Refractory CTCL]( [Outcomes in Resected Melanoma Influenced by Timing of Recurrence]( [Small-Town Patients Face Big Hurdles as Rural Hospitals Cut Cancer Care]( ADVERTISEMENT Exclusives & Features [Medical Malpractice Harms All Parties Involved, Documentary Reveals]( [For VP Candidate Tim Walz, Protecting Access to IVF Is Personal]( [A Balanced Bagging Classifier machine learning model-based web application to predict risk of febrile neutropenia in cancer patients]( Background: Although several models exist to predict risk of febrile neutropenia in cancer patients, there is still need to more accurately quantify this risk to minimize morbidity of and mortality... [READ MORE]( [Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.]( PURPOSE: Retrospective studies suggest that immunosuppressive treatment of immune-related adverse events (irAEs) impairs survival in patients with melanoma who received immune checkpoint inhibitors.... [READ MORE]( [11 cancer centers ranked by readmissions]( Discover the top 11 cancer hospitals with the lowest unplanned readmission rates, according to CMS data. See how they scored on quality of care measures. [READ MORE]( [The current therapeutic cancer vaccines landscape in non-small cell lung cancer.]( Currently, conventional immunotherapies for the treatment of non-small cell lung cancer (NSCLC) have low response rates and benefit only a minority of patients, particularly those with advanced... [READ MORE]( [Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.]( BACKGROUND: This study aimed to evaluate the effectiveness and safety of recombinant human endostatin (Rh-endostatin) plus programmed cell death 1 (PD-1) inhibitors and chemotherapy as first-line... [READ MORE]( [A Property of Everyday Health group]( © 2024 MedPage Today, LLC. MedPage Today is among the federally registered trademarks of MedPage Today, LLC, and may not be used by third parties without explicit permission. You have received this email because you have registered to receive emails at www.medpagetoday.com, with the email address: {EMAIL} [Manage Email Preferences]( | [Unsubscribe](lst=NL_Spec_Oncology_Update?xid=nl_mpt_Oncology_update_2024-08-09&mh=3c4cdd242849aa0e970f25e401732f81) | [Terms of Use]( | [Privacy Policy]( Technical Questions: feedback@medpagetoday.com 114 5th Avenue, 15th Floor New York, NY 10011